United Orthopedic Corporation AI Stock Analysis
United Orthopedic Corporation (4129) AI Stock Analysis
United Orthopedic Corporation
(TPEx:4129)
United Orthopedic scores moderately above average. Its financial profile is the main strength — rapid, consistent revenue growth, sharply expanded margins, improving return on equity and moderate leverage — supported by an undemanding 12.8x P/E and a high 6.31% dividend yield. Offsetting this, the share price is in a well-established downtrend, sitting below all key moving averages with negative MACD, and the decline has pushed momentum readings to deeply stretched levels. Thin free cash flow after heavy capital spending, a rising absolute debt balance and a margin plateau in the most recent year are the key fundamental risks limiting a higher score.
United Orthopedic Corporation (4129) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 7.05B
- Dividend Yield
- 6.19%
- Average Volume (3M)
- 244.36K
- Price to Earnings (P/E)
- 12.7
- Beta (1Y)
- 0.37
- Revenue Growth
- 18.91%
- EPS Growth
- 10.75%
- Country
- TW
- Employees
- 576
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
United Orthopedic Corporation Business Overview & Revenue Model
Company Description
United Orthopedic Corporation is a firm dedicated to the research, development, manufacturing, and global distribution of advanced orthopedic implants and specialized surgical instruments. The company's extensive product offerings address a wide spec...
United Orthopedic Corporation Financial Statement Overview
Summary
Strong fundamentals overall. The income statement (81) is the standout: revenue more than doubled to NT$5.66 billion with ~21% growth in the latest year, while gross margin expanded to 77.8%, operating margin to 13.1% and net income reached NT$562 million. The balance sheet (74) is sound, with equity funding 52% of assets, debt-to-equity of 0.50 and ROE improving every year to 13.7%. Cash flow (68) is the weakest pillar — operating cash flow of NT$1.03 billion is high quality at ~1.8x net income, but heavy capex of ~NT$760 million leaves free cash flow thin at NT$265 million and historically volatile. Watch the rising absolute debt load and the margin plateau in the latest year.
Income Statement
81Very PositiveBalance Sheet
74PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.06B | 5.66B | 4.65B | 3.93B | 3.16B | 2.57B |
| Gross Profit | 4.73B | 4.40B | 3.62B | 3.04B | 2.12B | 1.63B |
| EBITDA | 1.30B | 1.28B | 1.08B | 949.84M | 676.84M | 471.16M |
| Net Income | 551.87M | 562.50M | 456.43M | 384.20M | 221.53M | 52.27M |
Balance Sheet | ||||||
| Total Assets | 8.51B | 7.82B | 7.04B | 6.42B | 5.62B | 5.24B |
| Cash, Cash Equivalents and Short-Term Investments | 579.93M | 662.81M | 619.69M | 457.91M | 411.46M | 638.68M |
| Total Debt | 2.36B | 2.06B | 1.86B | 1.63B | 1.57B | 1.72B |
| Total Liabilities | 4.51B | 3.62B | 3.09B | 2.82B | 2.53B | 2.42B |
| Stockholders Equity | 3.90B | 4.10B | 3.85B | 3.50B | 2.99B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | -84.12M | 264.60M | 127.96M | -123.80M | -45.42M | 107.43M |
| Operating Cash Flow | 725.63M | 1.03B | 717.29M | 433.73M | 340.79M | 334.64M |
| Investing Cash Flow | -758.15M | -714.92M | -563.60M | -469.71M | -385.43M | -193.48M |
| Financing Cash Flow | 63.49M | -238.23M | -14.34M | 148.09M | -209.96M | -307.79M |
United Orthopedic Corporation Peers Comparison
Overall Rating
TW:410778Outperform- TW:412968Neutral
TW:315266Neutral
TW:416359Neutral
TW:649933Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4107 | 78Outperform | TWD 7.35B | 12.29 | ― | 5.12% | 10.16% | 17.15% |
| TW:4129 | 68Neutral | TWD 7.01B | 12.73 | ― | 6.19% | 18.91% | 10.75% |
| TW:3152 | 66Neutral | TWD 7.57B | 19.49 | ― | 7.67% | 1.88% | -26.76% |
| TW:4163 | 59Neutral | TWD 6.41B | 20.66 | ― | 2.78% | 4.16% | 40.82% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6499 | 33Underperform | TWD 7.33B | -16.44 | ― | ― | 69.62% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4129 | United Orthopedic Corporation | 72.70 | -42.36 | -36.82% | |
| TW:3152 | Advanced Ceramic X Corporation | 193.00 | -0.07 | -0.04% | |
| TW:4107 | Bioteque Corporation | 107.50 | -14.13 | -11.62% | |
| TW:4163 | Intai Technology Corp. | 126.00 | 29.44 | 30.48% | |
| TW:6499 | Medeon Biodesign, Inc. | 73.80 | -23.20 | -23.92% | |
| TW:6907 | Artery Technology Corporation | 123.50 | 74.84 | 153.82% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026